Selbæk Geir, Aarsland Dag, Ballard Clive, Engedal Knut, Langballe Ellen Melbye, Benth Jūratė Šaltytė, Bergh Sverre
Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway; Centre for Old Age Psychiatric Research, Innlandet Hospital Trust, Ottestad, Norway; HØKH, Research Centre, Akershus University Hospital, Lørenskog, Norway.
Center for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway; Department NVS, Karolinska Institutet, Center for Alzheimer Research, Stockholm, Sweden.
J Am Med Dir Assoc. 2016 May 1;17(5):464.e1-7. doi: 10.1016/j.jamda.2016.01.016. Epub 2016 Feb 28.
To assess the long-term mortality risk associated with antipsychotic drug (AP) use in nursing homes.
A longitudinal study with 5 assessments over a 75-month follow-up period.
A representative sample of nursing home patients in 4 Norwegian counties.
At baseline, 1163 patients were included. At the last follow-up, 98 patients were still alive.
Prevalent drug use at each assessment was registered. Level of dementia, neuropsychiatric symptoms, level of functioning, medical health, and use of restraints were recorded at each assessment. A Cox regression model with time-dependent psychotropic drug use as the main predictor was estimated and adjusted for confounders.
In unadjusted Cox regression, a lower mortality risk was associated with the use of other psychotropic drugs, but not APs, compared with nonusers. In the adjusted analysis, neither use of APs nor other psychiatric drugs was associated with increased mortality risk. Higher age, male gender, not being married, medical disease burden, lower level of functioning, more severe degree of dementia, and a higher number of drugs were all associated with increased mortality risk.
In this long-term study of nursing home patients, AP drug use was not associated with increased risk of mortality. This is in line with results from earlier studies of clinical samples, but contrasts with results from randomized controlled trials and registry-based studies. The findings should be interpreted with caution. Taking into account the modest benefit and high risk of adverse effects of AP drug use, nonpharmacological treatment remains the first-line treatment approach.
评估疗养院中使用抗精神病药物(AP)相关的长期死亡风险。
一项纵向研究,在75个月的随访期内进行5次评估。
挪威4个县疗养院患者的代表性样本。
基线时纳入1163名患者。在最后一次随访时,98名患者仍存活。
记录每次评估时的药物使用情况。每次评估时记录痴呆程度、神经精神症状、功能水平、健康状况和约束措施的使用情况。估计并调整以时间依赖的精神药物使用为主要预测因素的Cox回归模型,以校正混杂因素。
在未调整的Cox回归中,与未使用者相比,使用其他精神药物与较低的死亡风险相关,但与APs无关。在调整分析中,使用APs和其他精神药物均与死亡风险增加无关。年龄较大、男性、未婚、疾病负担、功能水平较低、痴呆程度较严重以及药物数量较多均与死亡风险增加相关。
在这项针对疗养院患者的长期研究中,使用AP药物与死亡风险增加无关。这与早期临床样本研究结果一致,但与随机对照试验和基于登记处的研究结果相反。这些发现应谨慎解释。考虑到AP药物使用的益处有限且不良反应风险较高,非药物治疗仍然是一线治疗方法。